Smallpox News and Research

RSS

Smallpox is a highly contagious disease caused by the variola virus, a member of the Orthopox virus family. It is one of the most devastating diseases known to humanity, with a mortality rate as high as 30%. In 1967, the World Health Organization embarked upon an intensified vaccination campaign to eliminate smallpox, which culminated in the successful eradication of the disease globally by 1980.

By the mid-1980s, there were only two known repositories of variola virus: the Institute of Virus Preparations in Russia, and the US CDC. The events in the US in September and October 2001 highlighted the risk that the variola virus might be used as an agent of bioterrorism. Governments around the world are taking precautionary measures to be ready to deal with a potential smallpox outbreak.

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel strategy for fighting the virus that causes AIDS by attempting to address one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity.

20 Oct 2010

New research coalition to design first human trial of mosaic HIV vaccine candidate

Duke University Medical Center vaccine experts have assembled an international team of investigators to design and implement the first human trial of a mosaic HIV vaccine candidate, a novel strategy that attempts to counter one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity

19 Oct 2010

MSF calls for donor countries to improve food aid nutrition standards on eve of World Food Day

Medecins Sans Frontieres (MSF) released a statement in advance of Saturday's World Food Day saying that the "world's biggest donors of food aid ... continued to supply and fund nutritionally 'substandard' food to developing countries, despite scientific evidence showing it was of little value in reducing child malnutrition," Reuters AlertNet reports.

18 Oct 2010

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio's intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine.

14 Oct 2010

NIH awards grant to Bavarian to advance early research in filoviruses

Bavarian Nordic A/S announced today that the company has received funding from the U.S. National Institutes of Health (NIH) to advance its early research in filoviruses (Ebola and Marburg virus).

14 Oct 2010

Mammography, vaccines still raise questions in consumers' minds

NPR reports on two preventive measures that, despite years of research, still have consumers wondering what to do.

12 Oct 2010

Inviragen, PharmaJet awarded NIAID contract to develop needle-free, easy to administer dengue vaccine

Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of a needle-free, easy to administer dengue vaccine. The award will fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen's tetravalent dengue vaccine, DENVax delivered with PharmaJet's convenient needle-free injection device.

8 Oct 2010

Aethlon Medical engages Fabiani & Company to assist in establishment of federal partnerships

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has engaged Fabiani & Company to assist in the establishment of federal partnerships that advance biodefense, cancer, and chronic infectious disease applications of the Aethlon Hemopurifier®.

30 Sep 2010

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that its unique Needle-Free Injection Therapy (NFIT) system, the Biojector 2000, is being utilized in a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the U.S. National Institutes of Health (NIH).

29 Sep 2010

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.

29 Sep 2010

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost vaccine regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa and South America.

29 Sep 2010

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.

21 Sep 2010

New study shows impact of violence on Palestinian, Israeli children

As another round of talks continues between Israelis and Palestinians, a new University of Michigan study documents the impact the violence has been inflicting on the region's children.

17 Sep 2010

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

16 Sep 2010

Doctors demonstrate the true impact of vaccination

With Children Back in School, Doctors Clear up Confusion and Demonstrate the True Impact of Vaccination

16 Sep 2010

395 new vaccines being developed for infectious diseases: PhRMA

Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.

10 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

New vaccines fact sheet released by Research!America

Research!America is highlighting the vital importance of vaccines with a new fact sheet in its Investment in Research Saves Lives and Money series. CDC recently reported that routine vaccination rates are increasing among teens aged 13-17, but for many diseases the vaccination rates are far below the CDC's recommended 90% mark. With kids heading back to school and flu season fast approaching, now is a good time to remind readers of the importance of vaccines and disease prevention.

8 Sep 2010

Aethlon Medical receives approval for Chronic HCV Infection treatment

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."

26 Aug 2010

U.S. Census Bureau features 'Immunization' on Profile America

Profile America — Saturday, August 21st. Many people die each year in the U.S. from diseases that could have been prevented by immunization. Many more experience pain, suffering and disability. That's why this is National Immunization Awareness Month — calling attention to the importance of people of all ages to get their shots.

21 Aug 2010

Smallpox News and Research

Further Reading

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

New research coalition to design first human trial of mosaic HIV vaccine candidate

MSF calls for donor countries to improve food aid nutrition standards on eve of World Food Day

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

NIH awards grant to Bavarian to advance early research in filoviruses

Mammography, vaccines still raise questions in consumers' minds

Inviragen, PharmaJet awarded NIAID contract to develop needle-free, easy to administer dengue vaccine

Aethlon Medical engages Fabiani & Company to assist in establishment of federal partnerships

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

New study shows impact of violence on Palestinian, Israeli children

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Doctors demonstrate the true impact of vaccination

395 new vaccines being developed for infectious diseases: PhRMA

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

New vaccines fact sheet released by Research!America

Aethlon Medical receives approval for Chronic HCV Infection treatment

U.S. Census Bureau features 'Immunization' on Profile America

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News